/
Other
Relapsed or Refractory
57
Pipeline Programs↗
45
Active Trials↗
59
Companies Involved↗
Relapsed or Refractory is a moderately active landscape with 57 programs across 59 companies. The most active players are Kyowa Kirin Co., Ltd., Shijiazhuang Yiling Pharmaceutical Co. Ltd, Dizal Pharmaceuticals. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 125
Phase 227
Phase 33
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
37 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 93% of 57 pipeline programs.
Analysis
Trial Status
170
clinical trials
Completed59 · 35%
Recruiting35 · 21%
Unknown status28 · 16%
Terminated27 · 16%
Withdrawn8 · 5%
Active, not recruiting5 · 3%
Other8 · 5%
Clinical Trials
Trial Activity
170 trials
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Recruiting·—·Phase 1·NCT05981209·27 enrolled
Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy
Recruiting·—·Phase 2·NCT04763616·37 enrolled
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Recruiting·—·Phase 2·NCT06316960·50 enrolled
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
Recruiting·—·Phase 2·NCT07148791·9 enrolled
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)